Clinical trials: FVC
Diffuse Cutaneous Systemic Sclerosis
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis
The purpose of this study is to evaluate efficacy, safety and tolerability of s.c. ianalumab administered in participants with diffuse cutaneous systemic sclerosis relative to placebo
- Trial name
- NCT06470048
- Testing
- Ianalumab
- Where
- 106 sites in United States, Argentina and 23 more
- Volunteers
- 201 people
- Sponsor
- Novartis Pharmaceuticals
Lung Diseases, Interstitial
INCHANGE - Nintedanib for Changes in Cough and Dyspnea in Patients Suffering From Chronic Fibrosing Interstitial Lung Disease With a Progressive Phenotype in Everyday Clinical Practice: a Real-world Evaluation
The primary objective of this study is to investigate the correlation between changes from baseline to 52 weeks in Forced Vital Capacity (FVC) [% pred.] and changes from baseline to 52 weeks in dyspnea score [points] or cough…
- Trial name
- NCT05151640
- Testing
- Nintedanib
- Where
- 31 sites in Bulgaria, Czechia and 3 more
- Volunteers
- 158 people
- Sponsor
- Boehringer Ingelheim
IPF
Prospective Evaluation of Biomarker Profiles in Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal, fibrotic disorder of the lung. The estimated prevalence is 30-80/100,000 in the United States with incidence estimates clearly rising.
- Trial name
- NCT02151435
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- University of Michigan
Idiopathic Pulmonary Fibrosis
Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)
PIPF-016 (ASCEND) is a Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of the Efficacy and Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis.
- Trial name
- ASCEND (NCT01366209)
- Testing
- Pirfenidone
- Where
- United States
- Volunteers
- 555 people
- Sponsor
- Genentech, Inc.
Phrenic Nerve Palsy
Does Saline Injection Around Phrenic Nerve Reduce Incidence of Diaphragmatic Paresis Following Interscalene Block?
Hemi-diaphragmatic palsy is a common undesirable effect of interscalene block, with an incidence of up to 100%. Mechanism of palsy is thought to be related to spread of local anaesthetic anterior to the anterior scalene muscle.
- Trial name
- NCT02893228
- Testing
- Saline, Levobupivacaine
- Where
- Ireland
- Volunteers
- 36 people
- Sponsor
- The Adelaide and Meath Hospital, incorporating The National Children's Hospital
Duchenne Muscular Dystrophy
Stacking Exercises Aid the Decline in FVC and Sick Time
Duchenne Muscular Dystrophy is complicated by weak breathing muscles and lung infections. "Lung volume recruitment" is a technique performed using a face mask or mouthpiece and a hand-held resuscitation bag to stack breaths…
- Trial name
- STEADFAST (NCT01999075)
- Testing
- Lung Volume Recruitment (LVR), Conventional Treatment
- Where
- 9 sites in Canada
- Volunteers
- 70 people
- Sponsor
- Children's Hospital of Eastern Ontario
Hyperkypohsis and Impaired Lung Function
Costovertebral Mobilization on Kyphotic Posture and Lung Function in Non-Smoker
Aim of this study is to find the effects of Costoverterbral Mobilization on Thoracic kyphosis and Lung function in non-smoker. A randomized control trial that will include total 44 participants.The first group will receive…
- Trial name
- NCT06530056
- Testing
- Costovertebral Mobilization+Conventional Therapy, Conventional Therapy
- Where
- Pakistan
- Volunteers
- 44 people
- Sponsor
- Riphah International University
Diaphragmatic Function, Lung Function
Pulmonary Function Changes and Diaphragmatic Paralysis Following Ultrasound Guided Supraclavicular Brachial Plexus Blockade: The Effects of Decreased Local Anesthetic Volume
This clinical trial is being conducted to study lung function and movement of the major muscle involved in breathing (the diaphragm) after a brachial plexus nerve block (nerve "freezing").
- Trial name
- NCT01048021
- Testing
- Supraclavicular Block
- Where
- Canada
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Manitoba
Idiopathic Pulmonary Fibrosis
Impulse Oscillometry for Prognostication in Idiopathic Pulmonary Fibrosis
A 5-point decline of forced vital capacity expressed as % predicted, over 6 months, is the current definition of disease progression (fast decline in lung function) in idiopathic pulmonary fibrosis.
- Trial name
- OSCILLO (NCT03898284)
- Testing
- Impulse Oscillometry
- Where
- 4 sites in France
- Volunteers
- 54 people
- Sponsor
- University Hospital, Tours